119-HR-3492 Data-Driven Journalist Impact Analysis

Summary

• Scope: The bill amends 18 U.S.C. §116 to criminalize “genital or bodily mutilation” and “chemical castration” of minors, defining these to include a list of gender‑related surgeries and the use of GnRH analogues and cross‑sex hormones for gender transition, with exceptions for conditions such as precocious puberty and specified DSD diagnoses. [1]Library of Congress — Text - H.R.3492 - 119th Congress (2025-2026): Protect Chi…
• Baseline: Current federal law targets female genital mutilation with similar interstate‑commerce jurisdictional elements; H.R. 3492 extends the section’s reach and penalties to additional procedures and medications. [2]Cornell Law School — 18 U.S. Code § 116 - Female genital mutilation | LII / Leg…
• High‑level effects: Immediate nationwide cessation of covered interventions for minors (outside exceptions); rare current utilization suggests limited direct medical‑spend reductions but introduces federal criminal exposure for clinicians/parents and shifts care toward mental‑health services, adult‑age deferral, or out‑of‑country options. [3]JAMA Network — Gender-Affirming Medications Among Transgender Adolescents in th…
• Evidence signal: Studies associate access to gender‑affirming medications with short‑term improvements in depression/suicidality among youth, while major reviews (e.g., the Cass Review) rate the overall evidence base as weak and recommend caution; NHS England now limits puberty blockers to research trials. [4]JAMA Network — Mental Health Outcomes in Transgender and Nonbinary Youths Recei…[5]PubMed (AAP Pediatrics) — Pubertal Suppression for Transgender Youth and Risk o…[6]Reuters — Evidence around youth gender care 'remarkably weak', says major Engli…[7]TIME — Children Will No Longer Be Able to Access Puberty Blockers at England Cl…

Economic Effects

Channeling costs vs. enforcement and substitution; figures below reflect best‑available published estimates and claims data.

• Direct medical spending: Utilization among minors is already low—fewer than 1 in 1,000 adolescents with commercial insurance received puberty blockers or cross‑sex hormones in 2018–2022—so gross federal savings from foregone treatment are modest relative to total health spending. [3]JAMA Network — Gender-Affirming Medications Among Transgender Adolescents in th…
• Procedural spending: Gender‑affirming surgeries in minors are rare (2.1 per 100,000 in 2019; almost all chest‑related), implying limited aggregate procedure savings, though families currently paying out‑of‑pocket would face cancellation rather than cost. [8]JAMA Network — Prevalence of Gender-Affirming Surgical Procedures Among Minors…
• Household outlays avoided vs. reallocated: Where covered today, families could avoid medication and surgical charges (e.g., median adolescent chest‑surgery charges ≈$29,886; blockers ranging roughly $1,200/month or implants $4,500–$18,000) but may incur new costs for mental‑health care, legal counsel, or travel/relocation. [9]JAMA Network — Gender-Affirming Chest Reconstruction Among Transgender and Gend…[10]PBS — When Transgender Kids Transition, Medical Risks are Both Known and Unknow…
• Provider/insurer impact: Pediatric and endocrine practices would face compliance costs and potential revenue loss from prohibited services; insurers see minor claims reductions offset by administrative updates to coverage policies and potential substitution (psychotherapy, crisis care). Evidence on net fiscal effect is indeterminate due to substitution. (No single definitive source; inference from utilization and pricing sources.) [3]JAMA Network — Gender-Affirming Medications Among Transgender Adolescents in th…[9]JAMA Network — Gender-Affirming Chest Reconstruction Among Transgender and Gend…
• Enforcement costs: New federal crimes imply investigation/prosecution and potential incarceration outlays (average annual federal COIF ≈ $44,090/inmate; FY2023). Given low baseline volumes, case counts may be small but non‑zero. [11]Federal Register / DOJ-BOP (via Justia) — Annual Determination of Average Cost…
• Litigation risk: Expect constitutional and administrative challenges (Commerce Clause scope; medical necessity determinations), creating legal expenditures for providers, insurers, and DOJ. The statute’s interstate‑commerce hooks mirror those added to the FGM law after Nagarwala. [12]Web search · turn 9 #3

Social Effects

• Access and identity: An estimated 724,000 U.S. youth aged 13–17 identify as transgender; for these families, the bill would foreclose medical options prior to age 18 except under narrow exceptions, shifting reliance to psychosocial support or adult‑age transition. [13]UCLA Williams Institute — New estimate: 2.8 million people aged 13 and older id…
• Mental health outcomes: Prospective and cross‑sectional studies associate access to puberty blockers/hormones with lower odds of moderate/severe depression and suicidality over 12 months and lower lifetime suicidal ideation, respectively; however, evidence quality and causal inference remain debated. [4]JAMA Network — Mental Health Outcomes in Transgender and Nonbinary Youths Recei…[5]PubMed (AAP Pediatrics) — Pubertal Suppression for Transgender Youth and Risk o…
• Evidence reviews and practice divergence: The Cass Review (England) judged adolescent evidence “remarkably weak,” informing NHS England’s decision to confine puberty blockers to clinical trials; major U.S. bodies (AAP, Endocrine Society) maintain supportive guidance pending systematic evidence updates. Net effect: heightened uncertainty and polarized clinical norms. [6]Reuters — Evidence around youth gender care 'remarkably weak', says major Engli…[7]TIME — Children Will No Longer Be Able to Access Puberty Blockers at England Cl…[14]AAP News — AAP reaffirms gender-affirming care policy, authorizes systematic re…[15]Endocrine Society — Endocrine Society Statement in Support of Gender-Affirming…
• Equity and geography: A federal ban eliminates interstate variation but may intensify stressors for transgender youth in all communities; conversely, it reduces the need for interstate travel to obtain or deny care. The direction of net well‑being effects is uncertain given conflicting evidence bases. [16]JAMA Network — Carbon Emissions From Patient Travel for Health Care | JAMA Netw…
• Parental and clinician liability: The bill criminalizes specified conduct and bars “mental/behavioral” indications from qualifying as “necessary to the health of the minor,” raising risk perceptions and likely chilling borderline clinical decisions (e.g., distinguishing cosmetic vs. reconstructive indications). [1]Library of Congress — Text - H.R.3492 - 119th Congress (2025-2026): Protect Chi…
• Legal climate: The U.S. Supreme Court’s June 18, 2025 decision upholding Tennessee’s youth‑care ban signals judicial receptivity to restrictions, reducing injunctive relief odds for challengers and shaping expectations for federal enforcement. [17]Reuters — US Supreme Court upholds Tennessee law banning youth transgender care

Environmental Effects

Impacts are second‑order relative to social/economic effects but are directionally assessable.

• Health‑sector footprint: U.S. health care accounts for ~8.5% of national greenhouse‑gas emissions; pharmaceuticals and clinical services are notable contributors. Reducing use of puberty blockers/hormones and surgeries would marginally lower this slice, though the absolute effect is very small. [18]Commonwealth Fund — How the U.S. Health Care System Contributes to Climate Chan…
• Travel substitution: If some families would otherwise travel frequently for care, a ban may reduce domestic trip emissions; alternatively, seeking care abroad would increase long‑haul travel emissions. Patient travel to health care generated an estimated 35.7 Mt CO2e in 2022 (424 g CO2e/mile), underscoring travel’s role in health‑related emissions. Direction of change depends on behavioral responses. [16]JAMA Network — Carbon Emissions From Patient Travel for Health Care | JAMA Netw…
• System responses: Telehealth for counseling (not prohibited) could substitute some in‑person visits and lower emissions at the margin, but medical interventions themselves would be proscribed for minors. [19]Web search · turn 13 #2

Temporal Analysis

• Immediate (0–12 months): Rapid cessation of covered treatments; cancellation of surgical waitlists; provider compliance audits and policy updates; potential spikes in crisis‑care demand among affected youth; first test‑case prosecutions possible. [3]JAMA Network — Gender-Affirming Medications Among Transgender Adolescents in th…
• Medium term (1–3 years): Litigation over scope (e.g., “supraphysiologic” dosing relative to biological sex; intent tests for surgeries done for non‑gender indications); potential DOJ enforcement guidance; insurance repricing toward mental‑health services; research shifts away from U.S. minors. [1]Library of Congress — Text - H.R.3492 - 119th Congress (2025-2026): Protect Chi…
• Long term (3+ years): Adult‑age deferral increases; some unmet needs persist; if enforcement yields convictions, incarceration costs accrue; broader care patterns align with NHS‑style caution absent new high‑quality evidence. [11]Federal Register / DOJ-BOP (via Justia) — Annual Determination of Average Cost…[6]Reuters — Evidence around youth gender care 'remarkably weak', says major Engli…

Unintended Consequences (Risks/Secondary Effects)

• Chilling effect on non‑gender indications: Although exceptions cover precocious puberty and specified physical illnesses, clinicians may avoid borderline uses of GnRH analogues (e.g., complex gynecologic pain in minors) due to fear of scrutiny over “purpose.” [1]Library of Congress — Text - H.R.3492 - 119th Congress (2025-2026): Protect Chi…
• Care disruptions and reversibility windows: Interrupting ongoing puberty suppression may affect bone accrual trajectories; long‑term studies suggest z‑scores fall during suppression and partially recover after years on gender‑affirming hormones, with persistent lumbar‑spine deficits in some cohorts—parameters that complicate stop‑start care. [20]Web search · turn 15 #2[21]Web search · turn 15 #1
• Black‑/gray‑market risk: Restrictions can shift some demand to unsupervised hormone sourcing, increasing safety risks; quantitative evidence is limited. (Risk inference; no definitive U.S. measure.)
• Data and research externalities: A ban forecloses U.S. clinical trials for minors, limiting domestic evidence generation and pushing policy to rely on foreign datasets (e.g., UK). [6]Reuters — Evidence around youth gender care 'remarkably weak', says major Engli…

Assessment

Overall stance: Neutral (analytical). The bill would standardize a national prohibition with narrow medical exceptions, likely reducing already‑rare utilization and related spending while introducing federal criminal exposure and enforcement costs. Social impacts hinge on contested evidence: some studies link access to improved short‑term mental‑health outcomes, whereas major reviews call the evidence base weak and urge caution. Legal headwinds for challengers appear stronger after the Supreme Court upheld a state‑level ban, yet Commerce Clause challenges to a federal criminal regime cannot be ruled out. Environmental effects are marginal. Policymakers should weigh low baseline utilization and uncertain substitution effects against the statute’s criminal liabilities and the current quality of evidence. [3]JAMA Network — Gender-Affirming Medications Among Transgender Adolescents in th…[4]JAMA Network — Mental Health Outcomes in Transgender and Nonbinary Youths Recei…[6]Reuters — Evidence around youth gender care 'remarkably weak', says major Engli…[17]Reuters — US Supreme Court upholds Tennessee law banning youth transgender care

Sourcing & Method Notes

1. Bill text and scope: Congress.gov official text for H.R. 3492 (Reported in House, Sept. 26, 2025). [1]Library of Congress — Text - H.R.3492 - 119th Congress (2025-2026): Protect Chi…
2. Baseline statute: Current 18 U.S.C. §116 (Cornell LII). [2]Cornell Law School — 18 U.S. Code § 116 - Female genital mutilation | LII / Leg…
3. Utilization (medications): JAMA Pediatrics research letter (2018–2022 private claims) and associated press coverage; figures rounded. [3]JAMA Network — Gender-Affirming Medications Among Transgender Adolescents in th…
4. Utilization (surgeries): JAMA Network Open insured‑population analysis (2019) on minors and adults. [8]JAMA Network — Prevalence of Gender-Affirming Surgical Procedures Among Minors…
5. Costs: Median adolescent chest‑surgery charges (JAMA Pediatrics, 2016–2019); puberty‑blocker cost ranges (PBS Frontline). [9]JAMA Network — Gender-Affirming Chest Reconstruction Among Transgender and Gend…[10]PBS — When Transgender Kids Transition, Medical Risks are Both Known and Unknow…
6. Mental‑health associations: Prospective cohort (JAMA Net Open 2022) and cross‑sectional adult recall (Pediatrics 2020). [4]JAMA Network — Mental Health Outcomes in Transgender and Nonbinary Youths Recei…[5]PubMed (AAP Pediatrics) — Pubertal Suppression for Transgender Youth and Risk o…
7. Evidence reviews and policy shifts: Cass Review reporting and NHS England blocker policy. [6]Reuters — Evidence around youth gender care 'remarkably weak', says major Engli…[7]TIME — Children Will No Longer Be Able to Access Puberty Blockers at England Cl…
8. Professional guidance: AAP 2018 policy reaffirmation (Aug. 2023) and Endocrine Society guideline resources/2024 statement. [14]AAP News — AAP reaffirms gender-affirming care policy, authorizes systematic re…[15]Endocrine Society — Endocrine Society Statement in Support of Gender-Affirming…
9. Legal context: SCOTUS decision upholding Tennessee’s youth‑care ban (June 18, 2025). [17]Reuters — US Supreme Court upholds Tennessee law banning youth transgender care
10. Enforcement cost reference: DOJ/BOP average cost of incarceration (FY2023 COIF). [11]Federal Register / DOJ-BOP (via Justia) — Annual Determination of Average Cost…
11. Environmental baselines: Commonwealth Fund explainer (8.5% of US emissions) and JAMA estimates for patient travel emissions. [18]Commonwealth Fund — How the U.S. Health Care System Contributes to Climate Chan…[16]JAMA Network — Carbon Emissions From Patient Travel for Health Care | JAMA Netw…